XML 81 R59.htm IDEA: XBRL DOCUMENT
v3.20.4

Collaboration and Profit-Sharing Agreements - Summary of Agreements (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | 8 Months Ended | 12 Months Ended | 15 Months Ended
--- | --- | --- | --- | --- | ---
Mar. 31, 2020 item | Nov. 30, 2019 USD ($) item | Jul. 31, 2018 USD ($) | May 31, 2018 USD ($) item | Mar. 31, 2017 USD ($) | May 31, 2015 USD ($) item | Dec. 31, 2020 USD ($) | Dec. 31, 2018 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2018 USD ($) | Jul. 31, 2017 USD ($) item
Revenue recognized |  |  |  |  |  |  | $ 5,767 |  | $ 92,302 |  |  |
Deferred revenue |  |  |  |  |  |  | 94,927 |  | 94,927 | $ 186,721 |  |
Deferred revenue, long-term |  |  |  |  |  |  | 73,984 |  | 73,984 | 163,207 |  |
Research and development |  |  |  |  |  |  |  |  | 157,996 | 96,898 | $ 90,654 |
Juno Therapeutics |  |  |  |  |  |  |  |  |  |  |  |
Total transaction price |  |  |  |  |  |  |  | $ 12,300 |  |  | 40,700 |
Allocable arrangement consideration - R&D Services Unit of Accounting |  |  |  |  |  |  | 10,700 |  | 10,700 |  |  |
Allocable arrangement consideration - Material rights |  |  |  |  |  |  | 30,000 |  | 30,000 |  |  |
Allergan |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  | 0 |  | 0 |  |  |
One time payment to acquire the license |  |  |  |  | $ 25,000 |  |  |  |  |  |  |
Collaboration and License Agreement | Juno Therapeutics |  |  |  |  |  |  |  |  |  |  |  |
Number of research areas | item |  |  |  |  |  | 3 |  |  |  |  |  |
Agreement term |  |  |  |  |  | 5 years |  |  |  |  |  |
Upfront fee received |  |  |  |  |  | $ 25,000 |  |  |  |  |  |
Number of milestones related to technical progress | item |  |  |  |  |  |  |  |  |  |  |  | 2
Potential fee receivable for each gene target licensed |  |  |  |  |  | $ 2,500 |  |  |  |  |  |
Number of additional licenses | item |  |  |  |  |  | 3 |  |  |  |  |  |
Transaction price research and development expenses funding |  |  |  |  |  |  |  |  |  |  | 2,900 |
Transaction price milestone payment received |  |  |  |  |  |  |  |  |  |  | 7,700 |
Milestone payment received under license agreement |  |  |  |  |  |  |  |  |  |  |  | $ 2,500
Amended Collaboration and License Agreement | Juno Therapeutics |  |  |  |  |  |  |  |  |  |  |  |
Number of research areas | item |  |  |  | 4 |  |  |  |  |  |  |  |
Additional upfront fee received |  |  |  | $ 5,000 |  |  |  |  |  |  |  |
Number of milestones related to technical progress | item |  |  |  | 2 |  |  |  |  |  |  |  |
Milestone payment receivable related to technical progress |  |  |  | $ 2,500 |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  |  | 800 | 11,300 | 1,700 |
Transaction price upfront fee received |  |  |  |  |  |  |  |  |  |  | 30,000 |
Amended Collaboration Agreement 2019 | Juno Therapeutics |  |  |  |  |  |  |  |  |  |  |  |
Agreement term |  | 5 years |  |  |  |  |  |  |  |  |  |
Extensions | item |  | 2 |  |  |  |  |  |  |  |  |  |
Extension period |  | 1 year |  |  |  |  |  |  |  |  |  |
Potential development milestone payments |  | $ 27,500 |  |  |  |  |  |  |  |  |  |
Potential regulatory milestone payments |  | 107,500 |  |  |  |  |  |  |  |  |  |
Potential licensed products milestone payments |  | 60,000 |  |  |  |  |  |  |  |  |  |
Total transaction price |  |  |  |  |  |  |  |  |  | 102,500 |  |
Amendment fee |  |  |  |  |  |  |  |  |  | 70,000 |  |
License Agreement, Exercise Fee |  |  |  |  |  |  |  |  |  | 500 |  |
Revenue recognized |  |  |  |  |  |  |  |  | 11,300 | 6,200 |  |
Deferred revenue |  |  |  |  |  |  | 90,700 |  | 90,700 | 32,000 |  |
Deferred revenue, long-term |  |  |  |  |  |  | 73,700 |  | 73,700 | $ 96,300 |  |
Transaction price upfront fee received |  | 70,000 |  |  |  |  |  |  |  |  |  |
First development and commercialization license payment received |  | $ 500 |  |  |  |  |  |  |  |  |  |
Strategic Alliance | Allergan |  |  |  |  |  |  |  |  |  |  |  |
Upfront fee received |  |  |  |  | $ 90,000 |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  | 62,100 |  |  |
Deferred revenue |  |  |  |  |  |  | $ 77,100 |  | $ 77,100 |  |  |
Number of Collaboration Development Programs | item | 5 |  |  |  |  |  |  |  |  |  |  |
Option exercise payment received |  |  | $ 15,000 |  |  |  |  |  |  |  |  |
Sponsored Research Agreement | Broad |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  |  |  |  | $ 12,500 |

X
- Definition Additional cash received from collaborators during the current + References No definition available. + Details
Name: | edit_AdditionalProceedsFromCollaborators
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of extensions to the agreement permitted under the agreement. + References No definition available. + Details
Name: | edit_AgreementExtensionNumber
Namespace Prefix: | edit_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of extensions to the agreement permitted under the agreement. + References No definition available. + Details
Name: | edit_AgreementExtensionPeriod
Namespace Prefix: | edit_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents element information pertaining to allocable arrangement consideration material rights. + References No definition available. + Details
Name: | edit_AllocableArrangementConsiderationMaterialRights
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The portion of potential future consideration under the arrangement allocated to the R&D Services Unit of Accounting at the inception of the agreement. + References No definition available. + Details
Name: | edit_AllocableArrangementConsiderationResearchAndDevelopmentServicesUnitOfAccounting
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of amendment fee earned during the period. + References No definition available. + Details
Name: | edit_LicenseAgreementAmendmentFee
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of exercise fee earned during the period. + References No definition available. + Details
Name: | edit_LicenseAgreementExerciseFee
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the milestone payment received under the license agreement. + References No definition available. + Details
Name: | edit_LicenseAgreementMilestonePaymentReceived
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of milestone payment receivable related to technical progress in research area. + References No definition available. + Details
Name: | edit_MilestonePaymentReceivableRelatedToTechnicalProgressInResearchArea
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The number of additional development and Commercialization License that can be purchased. + References No definition available. + Details
Name: | edit_NumberOfAdditionalDevelopmentAndCommercializationLicenseToBePurchased
Namespace Prefix: | edit_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of collaboration development programs for the treatment of ocular disorders under the exclusive license from the company. + References No definition available. + Details
Name: | edit_NumberOfCollaborationDevelopmentPrograms
Namespace Prefix: | edit_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of milestones related to technical progress. + References No definition available. + Details
Name: | edit_NumberOfMilestonesRelatedToTechnicalProgress
Namespace Prefix: | edit_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of research areas defined in the agreement. + References No definition available. + Details
Name: | edit_NumberOfResearchAreas
Namespace Prefix: | edit_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of one time payment to acquire the license. + References No definition available. + Details
Name: | edit_OneTimePaymentToAcquireLicense
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the amount of option exercise payment received. + References No definition available. + Details
Name: | edit_OptionExercisePaymentReceived
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The potential fees which the reporting entity could receive for achievement of regulatory milestones. + References No definition available. + Details
Name: | edit_PotentialDevelopmentMilestonePayments
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The potential fee which the reporting entity could receive from the collaborator for each gene target identified under the Development and Commercialization License + References No definition available. + Details
Name: | edit_PotentialFeeReceivableForGeneTargetsUnderDevelopmentAndCommercializationLicense
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents element information pertaining to potential regulatory licensed products milestone payments. + References No definition available. + Details
Name: | edit_PotentialRegulatoryLicensedProductsMilestonePayments
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The potential fees which the reporting entity could receive for achievement of regulatory milestones. + References No definition available. + Details
Name: | edit_PotentialRegulatoryMilestonePayments
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The term of the research program under the agreement. + References No definition available. + Details
Name: | edit_ResearchProgramTerm
Namespace Prefix: | edit_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents element information pertaining to revenue from contract with customer development and commercialization license received. + References No definition available. + Details
Name: | edit_RevenueFromContractWithCustomerDevelopmentAndCommercializationLicenseReceived
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of transaction price research and development expenses funding. + References No definition available. + Details
Name: | edit_RevenueFromContractWithCustomerResearchAndDevelopmentExpensesFunding
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of total transaction price. + References No definition available. + Details
Name: | edit_RevenueFromContractWithCustomerTransactionPrice
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of transaction price milestone payment received. + References No definition available. + Details
Name: | edit_RevenueFromContractWithCustomerTransactionPriceMilestonePaymentReceived
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of upfront fee received. + References No definition available. + Details
Name: | edit_RevenueFromContractWithCustomerUpfrontFeeReceived
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=edit_JunoTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=edit_AllerganMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=edit_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=edit_AmendedAndRestatedCollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=edit_AmendedCollaborationAgreement2019Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=edit_StrategicAllianceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=edit_SponsoredResearchAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=edit_BroadInstituteIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |